Medical diagnostic imaging and nuclear medicine

The retention gap technique in combination with on-column injection allows concentration of a large sample volume in the capillary column. Choice of the retention gap depends on the solvent used: the flooded zone after injection should be between

The retention gap technique in combination with on-column injection allows concentration of a large sample volume in the capillary column. Choice of the retention gap depends on the solvent used: the flooded zone after injection should be between

The retention gap technique in combination with on-column injection allows concentration of a large sample volume in the capillary column. Choice of the retention gap depends on the solvent used: the flooded zone after injection should be between

Reticle holder

Reticle with 100 divisions in 10mm (25mm diameter)

Reticle with crosshair (25mm diameter)

REV VALV 1/4NP .25PSI EPDM 1EA

RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC50s of 1, 2, 3, 4, 5 and 5 nM, respectively: also inhibits GSK-3β, TAK1, Jak2 and

RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC50s of 1, 2, 3, 4, 5 and 5 nM, respectively: also inhibits GSK-3β, TAK1, Jak2 and

RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC50s of 1, 2, 3, 4, 5 and 5 nM, respectively: also inhibits GSK-3β, TAK1, Jak2 and

RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC50s of 1, 2, 3, 4, 5 and 5 nM, respectively: also inhibits GSK-3β, TAK1, Jak2 and

RH SIDE CASING